Bank of New York Mellon Corp Increases Position in Actinium Pharmaceuticals, Inc. (NYSE:ATNM)

Bank of New York Mellon Corp boosted its position in Actinium Pharmaceuticals, Inc. (NYSE:ATNM) by 28.3% during the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 86,401 shares of the company’s stock after acquiring an additional 19,035 shares during the period. Bank of New York Mellon Corp owned 0.29% of Actinium Pharmaceuticals worth $639,000 at the end of the most recent reporting period.

A number of other hedge funds have also added to or reduced their stakes in the stock. Sanders Morris Harris LLC purchased a new position in shares of Actinium Pharmaceuticals in the first quarter worth $78,000. Virtu Financial LLC boosted its holdings in shares of Actinium Pharmaceuticals by 319.2% in the 1st quarter. Virtu Financial LLC now owns 82,029 shares of the company’s stock worth $642,000 after purchasing an additional 62,459 shares during the period. Finally, Vanguard Group Inc. lifted its stake in Actinium Pharmaceuticals by 6.0% in the first quarter. Vanguard Group Inc. now owns 1,446,326 shares of the company’s stock worth $11,325,000 after purchasing an additional 82,113 shares during the last quarter. 27.50% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

ATNM has been the subject of several research reports. B. Riley cut shares of Actinium Pharmaceuticals from a “buy” rating to a “neutral” rating and lowered their price target for the stock from $16.00 to $2.00 in a research report on Wednesday, August 7th. HC Wainwright dropped their target price on shares of Actinium Pharmaceuticals from $50.00 to $4.00 and set a “buy” rating on the stock in a research report on Tuesday, August 6th. StockNews.com lowered shares of Actinium Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Wednesday, September 18th. Finally, Maxim Group decreased their price objective on Actinium Pharmaceuticals from $30.00 to $5.00 and set a “buy” rating on the stock in a report on Tuesday, August 6th. One analyst has rated the stock with a sell rating, one has issued a hold rating and four have assigned a buy rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $11.40.

Actinium Pharmaceuticals Stock Up 2.2 %

Shares of ATNM opened at $1.84 on Tuesday. Actinium Pharmaceuticals, Inc. has a 1 year low of $1.33 and a 1 year high of $10.24. The firm has a 50-day moving average of $3.56. The stock has a market cap of $54.80 million, a PE ratio of -1.08 and a beta of 0.14.

Actinium Pharmaceuticals (NYSE:ATNM) last posted its quarterly earnings data on Monday, August 5th. The company reported ($0.38) EPS for the quarter, beating analysts’ consensus estimates of ($0.40) by $0.02. Research analysts forecast that Actinium Pharmaceuticals, Inc. will post -1.38 EPS for the current fiscal year.

Actinium Pharmaceuticals Company Profile

Actinium Pharmaceuticals, Inc develops antibody radiation conjugates and other targeted radiotherapies intended to improve outcomes for people who have failed existing oncology therapies. Its Iomab-B is an induction and conditioning agent prior to bone marrow transplant in patients with relapsed and refractory acute myeloid leukemia (r/r AML).